Mediaboss Marketing

The European Union's enlargement and its capacity to prepare for systemic shocks and to counter foreign interference in its information space were the focuses of attention when the Commission for Citizenship, Governance, Institutional and External Affairs (CIVEX) met on 18 April.

Enlargement, strategic foresight and foreign interference are all subjects of opinions that the European Committee of the Regions will adopt in the coming months.

Members also discussed how the public and private sector are cooperating to help the inclusion of refugees from Ukraine, with contributions from the OECD and Eurochambres, and on how the EU can follow up in the longer term on the lessons about democratic innovation learned from the Conference on the Future of Europe.

Enlargement Package 2022

The CIVEX commission adopted, with some amendments, an assessment of the European Commission's 2022 Communication on EU Enlargement Policy. The draft opinion emphasises the importance of advancing reforms of public administration and building up the capacity of local and regional administrations, noting that 70% of the EU's laws require implementation at the sub-national level. The debate included a number of interventions specifically related to Trkiye, which will hold general elections on 14 May. The opinion does not cover Ukraine and Moldova, which became candidates for EU membership in June 2022.

The rapporteur, Anna Magyar (HU/ECR), member of the County Council of Csongrd Megye, said: "There is a consensus on the EU side that enlargement policy is a strategic instrument that contributes to peace and security in Europe. The current war has only highlighted this approach. The most important task in the current geopolitical situation is for the European Committee of the Regions to contribute to a common reflection on how the enlargement process can be put at the service of the EU's strategic objectives. The added value of the Committee of the Regions is that we can see what the application of EU legislation entails at the local level. This valuable knowledge must be passed on to the candidate countries, and EU institutions must be made aware of the importance of taking into account the experience of regional and local governments when making decisions."

The European Committee of the Regions will on 4-5 May hold its annual Enlargement Days, a conference that brings together local and regional politicians from Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, Serbia, Trkiye and for the first time Ukraine and Moldova.

Strategic foresight as an instrument of EU governance and better regulation

Members of the commission held a preliminary exchange of views on how strategic foresight a structured, systemic and collective way to anticipate change can be used to be used to improve EU governance and regulations. The exchange lays the ground for an opinion that is scheduled for adoption in October. The European Commission has been investing a strategic foresight to build up resilience and capacity to adapt to change, shocks and crises. The CoR's opinion will explore how local and regional authorities and the CoR can contribute to a system of 'anticipatory governance'.

The rapporteur, Piero Mauro Zanin (IT/EPP), President of the Regional Council of Friuli-Venezia Giulia, said: "The dramatic events of the last few years (from the pandemic to Russia's aggression on Ukraine) make clear that applying strategic foresight is a fundamental need for regional and local policy-makers, in order to implement 'future-proof' policies and regulations. Through this opinion, the CoR can strengthen its role and underline how LRAs can adopt a new anticipatory governance" model, based on the capability to identify and assess the next events and trends since their first weak signals". The opinion also aims at stressing the importance of strategic foresight as a governance and policy-planning tool, and especially as one of the most essential parts of better regulation. The CoR can moreover promote some ad-hoc educational and training actions, also targeted at LRAs officers, to develop a common mind-set so that all Europe's regions approach foresight consistently, and can effectively share their experiences and best practices."

The role of local and regional authorities in countering foreign information manipulation and interferenceThe meeting saw an initial debate on an own-initiative report by the European Committee of the Regions on countering foreign interference in the information space. The opinion is being fast-tracked, and will build on recent CoR opinions on European democracy action plan, supporting media, countering disinformation, reinforcing the integrity of elections, and adding hate speech and hate crimes to the list of EU crimes.

The rapporteur, Gustaw Marek Brzezin (PL/EPP), President of Warmisko-Mazurskie Region, said: "Local and regional media play important role in countering disinformation and therefore they should be supported by local and regional authorities. Only by working together, European, national, local and regional level, we can prevent, detect and expose manipulation of information. We must broaden the knowledge of representatives of local and regional authorities in raising public awareness to the mechanisms of disinformation."

Debates on Ukrainian refugees and the follow-up to the Conference on the wFuture of EuropeThe work areas of the CIVEX commission include among other topics the EU's institutional affairs, migration, and external affairs. These were topics that were in focus in two separate debates held at the meeting.

A discussion about "New avenues for European democracy: lessons learnt from the Conference on the Future of Europe" considered how to embed participatory democracy into the EU decision-making cycle. The CoR is building on the Conference on the Future of Europe, a year-long exercise in which citizens contributed to debates on the future of Europe, through projects and initiatives that support democratic innovation at the local and regional level and through its consultative works and political debates.

The second thematic debate was on how the public and private sector can cooperate to help the inclusion of refugees,

The second thematic debate was on how the public and private sector can cooperate to help the inclusion of refugees, and will contribute to a study commissioned by the CoR and the OECD. The study, 'Action by sub-national governments to address Ukrainian refugees' needs', will feed into the CoR's Annual Report on the State of Regions and Cities in the European Union, which will be presented in October.

Thecommission meeting can be re-watchedon the event page.

View post:
A larger and more resilient EU in spotlight at CIVEX meeting - European Committee of the Regions

Seventh approved indication for RINVOQ in the European Union (EU) and the first and only oral Janus Kinase (JAK) inhibitor approved to treat adult patients with moderately to severely active Crohn's disease

Third gastroenterology indication approved across AbbVie's Inflammatory Bowel Disease portfolio in less than a year

A significantly higher proportion of patients treated with RINVOQ achieved the co-primary endpoints of endoscopic response and clinical remission and the key secondary endpoint of corticosteroid-free clinical remission at weeks 12 and 52 compared to placebo1-4; safety results in Crohn's disease were generally consistent with the known safety profile of RINVOQ1,5-9

Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract and is progressive, potentially producing complications that require urgent medical care, including surgery10,11

NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.1-4

"The EC approval of RINVOQ in Crohn's disease is a significant milestone in offering patients the first and only once-daily oral treatment that can provide endoscopic improvement, and sustained symptom relief, making a difference in their daily lives," saidThomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "With existing therapies, not all patients are able to achieve adequate disease control to meet their treatment goals, which is why we continue to embrace the challenge of expanding our IBD portfolio with new treatment options."

The EC approval is supported by data from two induction studies, U-EXCEED and U-EXCEL, and the U-ENDURE maintenance study.1 Statistical significance was achieved for the co-primary endpoints and key secondary endpoints with RINVOQ 45 mg in the induction studies and RINVOQ 15 mg and 30 mg in the maintenance study compared to placebo.1-4

Co-Primary Endpoint Results from the Phase 3 program include1-4:

Key Secondary and Additional Endpoints include:

"Crohn's disease is a burden that can present patients with daily, often uncomfortable challenges,"saidLaurent Peyrin-Biroulet, M.D., Ph.D., professor of gastroenterology and head of the Inflammatory Bowel Disease group at the Gastroenterology Department, University Hospital of Nancy, France."These studies demonstrated RINVOQ's ability to achieve key treatment targets, including endoscopic outcomes and symptomatic relief, that are critical for patients and beneficial for long-term care."

The safety profile of RINVOQ in Crohn's disease was generally consistent with the known safety profile of RINVOQ.1-4Similar rates of serious adverse events including serious infections, were observed between patients receiving RINVOQ and placebo.1-4 The most common adverse events included nasopharyngitis, acne and COVID-19 in the RINVOQ treatment group.1-4 Reports of malignancy, major cardiovascular events, venous thromboembolic events and gastrointestinal perforation were infrequently observed (<1.0 Events/100 Patient-Years).

RINVOQ is approved in the EU for the treatment of adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, adults and adolescents with atopic dermatitis and now Crohn's disease.1,5-9

About Crohn's DiseaseCrohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain.10,11It is a progressive disease, meaning it gets worse over time in a substantial proportion of patients or may develop complications that require urgent medical care, including surgery.10,11Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the diseasenot only physically, but also emotionally and economically.10,11

About the U-EXCEED and U-EXCEL Inductions Studies, and the U-ENDURE Maintenance Study1-4The three Phase 3 studies are multicenter, randomized, double-blind, placebo-controlled studies to evaluate the efficacy and safety of RINVOQ 45 mg as induction therapy and RINVOQ 15 mg and 30 mg as maintenance therapy in patients with moderately to severely active Crohn's disease. Topline results of the U-EXCEED and U-EXCEL induction studies were announced in December 2021and February 2022. Topline results of the U-ENDURE maintenance study were announced in May 2022. More information can be found onwww.clinicaltrials.gov(U-EXCEED:NCT03345836 , U-EXCEL:NCT03345849 , U-ENDURE:NCT03345823).

About RINVOQ (upadacitinib)Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible Janus Kinase (JAK) inhibitor.1 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1

Phase 3 trials of upadacitinib (RINVOQ) in giant cell arteritis and Takayasu arteritis are ongoing.1,12-14

EU Indications and Important Safety Information about RINVOQ (upadacitinib)1

Indications

Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Atopic dermatitis

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease

RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

ContraindicationsRINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for useRINVOQ should only be used if no suitable treatment alternatives are available in patients:

Use in patients 65 years of age and olderConsidering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients 65 years of age, as observed in a large randomised study of tofacitinib (another JAK inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients 65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products Use in combination with other potent immunosuppressants is not recommended.

Serious infectionsSerious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients 65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

TuberculosisPatients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivationViral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

VaccinationThe use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised activecontrolled study of tofacitinib (another JAK inhibitor) in RA patients 50 years of age with 1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients 65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalitiesTreatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal PerforationsEvents of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from postmarketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular eventsMACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients 50 years of age with 1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients 65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

LipidsRINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevationsTreatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolismEvents of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients 50 years of age with 1 additional CV risk factor, a dosedependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Hypersensitivity reactionsSerious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Adverse reactions

The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg in adolescents was similar to that in adults. The safety and efficacy of the 30 mg dose in adolescents are still being investigated.

The most commonly reported adverse reactions in the UC and CD trials (3% of patients) with RINVOQ 45mg, 30mg or 15mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropaenia, rash, pneumonia, hypercholesterolemia, bronchitis, aspartate transaminase increased, fatigue, folliculitis, alanine transaminase increased, herpes simplex, and influenza.

The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA.

Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

The most common serious adverse reactions were serious infections.

The safety profile of upadacitinib with longterm treatment was generally similar to the safety profile during the placebocontrolled period across indications.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in GastroenterologyWith a robust clinical trial program, AbbVie is committed to cutting-edge research to drive exciting developments in inflammatory bowel diseases (IBD), like ulcerative colitis and Crohn's disease. By innovating, learning and adapting, AbbVie aspires to eliminate the burden of IBD and make a positive long-term impact on the lives of people with IBD. For more information on AbbVie in gastroenterology, visithttps://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/gastroenterology.html.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie onTwitter,Facebook,LinkedInorInstagram.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, uses of future or conditional verbs generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

* Endoscopic response is defined as a decrease in simple endoscopic score for Crohn's disease (SES-CD) of >50% from baseline (or at least a 2-point reduction from baseline in patients with a baseline score of 4) of the induction. Clinical remission per SF/AP is defined as average daily very soft or liquid stool frequency 2.8 AND abdominal pain score 1.0 and neither greater than baseline. Corticosteroid-free clinical remission is defined as discontinuation of corticosteroid and achievement of clinical remission among subjects on corticosteroid at baseline in the induction studies and is defined as without corticosteroid use for 90 days and achievement of clinical remission in the maintenance study. Mucosal healing is defined as SES-CD ulcerated surface subscore of 0 in patients with SES-CD ulcerated surface subscore 1 at baseline. Mucosal healing was a prespecified endpoint, not controlled for multiplicity.

SOURCE AbbVie

View post:
AbbVie Announces European Commission Approval of RINVOQ ... - AbbVie

The government of Tanzania, the African Development Bank, and the French Development Agency (AFD) have signed agreements for two development project loans worth $300 million. The funds will finance the construction of the 87.8-megawatt Kakono Hydropower Plant located in Kagera region in the northern part of Tanzania. The project also received a grant of EURO 36 million from the European Union.

Tanzania is dependent on hydropower and thermal power plantsmainly gas-firedfor its electricity supply. However, it has considerable untapped renewable energy potential to meet its rapid growth while taking a low-carbon path.

A coalition of development partners are financing the Kakono Hydropower Project, intended to increase renewable generation capacity and reduce hydrological risk via a dam located on a new watershed that is less affected by droughts. The signing ceremony took place on the 15th of March 2023 in Dar es Salaam.

The Kakono Hydropower Plant is the result of close collaboration between the African Development Bank, Agence francaise de developpement, and the European Union. These institutions are co-financing this project with a $ 161.47 million African Development Bank soft loan, a EURO 110 million soft loan from French Development Agency, and EURO 36 million grant from the European Union.

The Kakono Hydropower Project which will be implemented by Tanzanias Electric Supply Company (TANESCO), will reduce greenhouse gas emissions by 216,065 metric tons per year, and comply with the best international environmental and social standards.

The project will serve 4 million people and increase the service coverage rate by around 7% of the population. It is expected to have a major impact on the economic development of this rapidly growing zone, which lies at the heart of the Great Lakes region. This project will boost industrialization and spur economic growth in Tanzania and the neighboring countries and will strengthen Tanzanias leading position within the East African Community.

Alongside construction of the new hydropower plant, there will also be associated infrastructure built, including the upgrading of the existing Kyaka substation and a new 39-kilometer 220-kilovolt transmission line, and capacity building support for TANESCO.

Following the ceremony participants expressed their support for the project.

African Development Bank Country Manager for Tanzania Patricia Laverley observed that when completed, the Kakono Hydropower Plant would serve approximately four million people, small-medium enterprises, and mining companies in the northwestern part of the country.

She added: The construction of the new power plant will help to improve TANESCOs financial sustainability arising from the decommissioning of the diesel-based power plants in the Kagera Region. The economic benefits derived from the supply of affordable power will be immense. We can expect to see marked improvement in the quality of life for people in the Kagera region and in Tanzania more broadly. These tremendous gains will contribute to building a more competitive economy in Tanzania, under the leadership of President Samia Suluhu Hassan.

Ambassador Nabil Hajlaoui said: We have heard President SamiaSuluhus message. She aims to generate 5 gigawatts of electricity by 2025. France is ready to be part of this journey by investing in power generation and transmission projects to meet the rapidly growing electricity demand, while reducing the carbon intensity of its energy mix.

AFD Country Director Celine Robert noted: We are delighted with the signing of this project, which is fully in line with international climate objectives and AFDs strong commitments in that regard. This investment will have major impact on economic development and on population well-being as the infrastructure will answer the power needs of 3 to 4 million people. This signing represents an important milestone and confirms that the cooperation between Government and AFD is deepening.

Read more:
European Union, and France invest $300 million in Tanzanias ... - African Development Bank

Join us for our upcoming hackathon, focused on LGBTQIA+ rights and issues, where innovation and collaboration will take center stage. This exciting event will bring together bright minds from across the European Union and South Asia, to foster cross-cultural dialogue, raise awareness, and encourage innovative ideas to tackle the challenges faced by the LGBTQIA+ community.

The online hackathon will be held on 17th May, where the top 3 projects will be selected to compete in the thrilling physical hackathon in Colombo, Sri Lanka from 5th to 8th June. The winner of our hackathon will have the incredible opportunity to represent their winning project in the international hackathon in Germany this October!

As a participant, you will have the opportunity to showcase your skills, work with a diverse group of individuals, and make a real impact on the world. Don't miss out on this amazing opportunity to be part of a global movement for LGBTQIA+ rights. Register now to join us in making a positive impact and creating innovative solutions that can change lives.

Visit our partner Hackerearth's website for more information and to register. We look forward to seeing you at the hackathon!

See the original post:
Global Hackathon : Strengthening Dialogue and Cooperation ... - Friedrich Naumann Foundation

In the eyes of the European Union, Taiwan is a thriving democracy, a like-minded partner, an open and dynamic economy, an attractive destination for investment and an unbeatable producer of cutting-edge technology that keeps the modern world running.

But despite lucrative trade ties and shared core values, the EU does not recognise Taiwan as an independent, sovereign nation.

Why is that?

According to customary international law, a country must meet four essential criteria in order to attain statehood: a defined territory, a settled population, a functioning government and the ability to engage in diplomatic relations, which effectively amounts to international recognition.

In practice, Taiwan, whose official name is the Republic of China (ROC), fulfils the first three requirements but falls woefully short in the fourth one: the island of almost 24 million citizens has diplomatic relations with only 12 countries, all of them small-sized, and the Holy See.

This lack of endorsement stems from the One China policy, a principle that recognises the People's Republic of China (PRC), based in the mainland and ruled by the Chinese Communist Party, as the sole, legitimate government of the country under the name of China.

The One China policy is today followed by the vast majority of the international community, including the EU institutions and its 27 member states, and its history dates all the way back to World War II.

Watch the video above to find out more.

Here is the original post:
Explained: Why the EU doesn't consider Taiwan a sovereign country - Euronews